Three-Dimensional Structure of a Fluorescein–Fab Complex Crystallized in 2-Methyl-2,4-pentanediol

James N. Herron, Xiao-min He, Martha L. Mason, Edward W. Voss, Jr., and Allen B. Edmundson Department of Biology, University of Utah, Salt Lake City, Utah 84112 and Department of Microbiology, University of Illinois, Urbana-Champaign, Illinois 61081

ABSTRACT The crystal structure of a fluorescein-Fab (4-4-20) complex was determined at 2.7 Å resolution by molecular replacement methods. The starting model was the refined 2.7 A structure of unliganded Fab from an autoantibody (BV04-01) with specificity for singlestranded DNA. In the 4-4-20 complex fluorescein fits tightly into a relatively deep slot formed by a network of tryptophan and tyrosine side chains. The planar xanthonyl ring of the hapten is accommodated at the bottom of the slot while the phenylcarboxyl group interfaces with solvent. Tyrosine 37 (light chain) and tryptophan 33 (heavy chain) flank the xanthonyl group and tryptophan 101 (light chain) provides the floor of the combining site. Tyrosine 103 (heavy chain) is situated near the phenyl ring of the hapten and tyrosine 102 (heavy chain) forms part of the boundary of the slot. Histidine 31 and arginine 39 of the light chain are located in positions adjacent to the two enolic groups at opposite ends of the xanthonyl ring, and thus account for neutralization of one of two negative charges in the haptenic dianion. Formation of an enol-arginine ion pair in a region of low dielectric constant may account for an incremental increase in affinity of 2-3 orders of magnitude in the 4-4-20 molecule relative to other members of an idiotypic family of monoclonal antifluorescyl antibodies. The phenyl carboxyl group of fluorescein appears to be hydrogen bonded to the phenolic hydroxyl group of tyrosine 37 of the light chain. A molecule of 2-methyl-2,4-pentanediol (MPD), trapped in the interface of the variable domains just below the fluorescein binding site, may be partly responsible for the decrease in affinity for the hapten in MPD.

Key words: antifluorescyl monoclonal antibody, high-affinity binding site, effects of MPD on hapten binding

INTRODUCTION

The antifluorescein system is well suited for studying the molecular basis of antigenic specificity because it offers both a wide range of binding affinities $(10^5-10^{10} \text{ M}^{-1})$, and a variety of experimental

techniques for correlating antigen binding affinities, kinetics, and thermodynamics. 1-9 Furthermore, it has been possible to develop a family of idiotypically cross-reactive antibodies in which individual monoclonals vary in affinity over a 1000-fold range.9 Amino acid sequences recently determined for eight of these antibodies in one of our laboratories (E.W.V.) show that at least six were derived from the same germline variable genes. Thus, the antifluorescein idiotype family can be used to further the understanding of both idiotypy and affinity maturation. In this report, we describe the threedimensional structure of a complex of dianionic fluorescein with the antigen-binding fragment from the antibody (4-4-20) with the highest affinity in this idiotype family.

The 4-4-20 monoclonal is an IgG_{2a} (k) antibody that binds fluorescein with an association constant of 3.4 \times 10¹⁰ M⁻¹ in aqueous solution. This affinity decreases 300-fold in 47% (v/v) 2-methyl-2,4pentanediol (MPD), the solvent used for cocrystallization of the 4-4-20 Fab with fluorescein hapten.5 The antibody is a highly specialized molecule that does not cross-react with rhodamine compounds. 1,6 In the formation of a complex with the 4-4-20 antibody, fluorescein satisfied criteria for a site-filling ligand, with the xanthonyl ring behaving as the "immunodominant" moiety.6 Despite its relatively large size and distinctive chemical features, fluorescein induces a diverse immune response when injected as a conjugate with keyhole limpet hemocyanin (KLH).1,7-9 Interpretation of binding studies have sometimes been ambiguous with heterogeneous populations of antibodies. It therefore seemed appropriate to determine the mode of binding in a single molecular species, particularly one with high affinity for fluorescein.

This crystal system affords a rare opportunity to consider both the structural features responsible for high-affinity binding and the effects of solvent in lowering that affinity. The complex will also be ex-



Received January 20, 1989; revision accepted March 24, 1989.

Address reprint requests to A.B. Edmundson, Department of Biology, University of Utah, Salt Lake City, UT 84112.

James N. Herron's present address is Department of Pharmaceutics, University of Utah, Salt Lake City, UT 84112.

amined to assess the influence of the carrier protein (KLH) on the location and orientation of the hapten in the combining site. In the preparation of the immunogen, molecules of the isothiocyanate derivative of fluorescein amine (isomer I) were coupled to KLH, with the principal reactions presumed to involve the ϵ -amino group of lysine side chains. The 4-4-20 hybridoma was obtained by fusion of hyperimmunesplenocytes stimulated with the fluorescein–KLH conjugate.

The present work adds to previous crystallographic studies of complexes in which small molecules were diffused into crystals of human and murine immunoglobulin fragments with binding sites shaped like cavities or shallow depressions. 10-15 These studies have helped define the molecular basis of low- and medium-affinity interactions and have provided the background to broaden our understanding of antigenic specificity. Block-end types of interactions over large external surfaces have been studied in cocrystals of Fab molecules and protein antigens like lysozyme and influenza neuraminidase.16-19 Antibodies binding DNA have grooves as potential combining sites, and cocrystals of Fabs and oligodeoxynucleotides are currently being subjected to X-ray analyses. 20-23 The structure of an unliganded Fab (J539) with specificity for galactan in carbohydrates has also been determined.24 A model for the binding of the ligand was proposed on the basis of solution studies and the structure of the combining site.

Recently, a single-chain antigen-binding protein²⁵ was constructed to simulate the Fv fragment of the 4-4-20 antibody (an Fv fragment consists of the "variable" domains of the heavy and light chains). The three-dimensional structure of the 4-4-20 Fab should prove very useful in assessing the properties and applications of the single chain protein.

MATERIALS AND METHODS Preparation of Fluorescein-Fab Complex

Procedures for the isolation and purification of the 4-4-20 monoclonal antibody and fluorescein-Fab complex were described in a previous article.⁵ In outline the Fab fragments were prepared by hydrolysis of fluorescein-IgG complexes with papain. Liganded Fabs were purified by chromatofocusing on 15 ml Pharmacia PBE 94 columns, with a linear pH gradient of 9 to 6 formed with Pharmacia Polybuffer 96. Because of potential destructive effects of dye-sensitized photooxidation by free fluorescein, it was necessary to protect the liganded protein from light at all stages of the procedures. Columns, tubes, and vessels used in affinity chromatography, chromatofocusing, dialysis, enzymatic hydrolysis, and crystallization trials were all covered with aluminum foil. All manipulations and transfers were carried out in reduced light. Under such precautions the liganded Fab was eluted from the chromatofocusing column as a single component with a pl of 7.2

After dialysis against 50 mM sodium phosphate, pH 7.2, the solution of the fluorescein-Fab complex was concentrated to 25 mg/ml by ultrafiltration (the acceptable range for crystallization was 10-30 mg/ml). The complex was crystallized by a batch method in an environment with strict light and temperature (12-14°C) control. Graded aliquots of MPD were added to 40 µ.l samples of the liganded protein in flat-bottomed glass vials. Crystals appeared in 2 days with final MPD concentrations of 38-60% (v/v), the optimum being ~47%. Bladed crystals suitable for X-ray analysis grew to dimensions of 0.6 \times 0.35 \times 0.3 mm (1 \times w \times d) in 1–2 months. Green fluorescence, attributable to the dissociation of fluorescein from the complex in MPD, was observed in each crystallization tube.

Collection of X-Ray Diffraction Data

The fluorescein–Fab complex crystallized in the triclinic space group P1, with a=58.3, b=43.9, and c=42.5 Å; $\alpha=82.1$, $\beta=87.3$, and $\gamma=84.6^{\circ}.^{5}$ Crystals disintegrated at temperatures >22°C, but were mechanically stable even in the X-ray beam when the ambient temperature was maintained at $12-14^{\circ}$ C. Temperature instability of the complex in MPD had also been noted in solution. For example, irreversible increases in the standard free-energy changes (ΔG°) in the liganded IgG and Fab molecules occurred in 40% MPD at relatively low temperatures (transition temperature of 30°C).

A single crystal was used to collect X-ray diffraction data to 2.7 Å resolution with a Nicolet P21 diffractometer operated at 40 kV and 35 mA (CuK_{α} radiation). The data set included 11,116 unique reflections, of which 9120 (82.0%) were observed at intensity levels >1.5 standard deviations (based on counting statistics).

Determination of the Three-Dimensional Structure of the Liganded Fab

The fluorescein–Fab complex crystallized in the same space group (P1) as the unliganded Fab of the BV04-01 IgG_{2b} autoantibody, with specificity for single-stranded DNA.^{5,26} Unit cell dimensions for the two crystals were nearly identical and one of us (X-M.H.) found by molecular replacement methods^{27–30} that the proteins were in the same orientations in these unit cells. With the refined 2.7 Å structure of the BV04-01 Fab as starting model, the orientation of the 4-4-20 Fab was determined more accurately with rotation function programs.

Crystallographic refinement ^{31,32} of the structure was initiated with the X-ray diffraction data⁵ for the 4-4-20 Fab and the atomic model of the BV04-01 Fab.^{22,23} After 30 cycles of refinement with 2.7-6.0 Å data (8304 reflections), the amino acid sequences



TABLE I. Refinement Data

	Actual rms deviation	Target value
Average ΔF^*	46.6	
R-factor	0.215	
$\langle B \rangle$ in Å ² †	15.5	
No. of reflections, $I > 1.5 \sigma(I)^{\frac{1}{4}}$	8304	
Root mean square (rms) deviations		
From ideal distance (Å)		
Bond distance	0.028	0.03
Angle distance	0.055	0.04
Planar 1-4 distance	0.032	0.03
Hydrogen bond distance [§]	0.132	0.05
rms deviation from planarity (A)	0.014	0.025
rms deviation from ideal chirality (Å3)	0.210	0.150
rms deviation from permitted contact distances (Å)		
Single torsion contacts	0.280	0.500
Multiple torsion contacts	0.400	0.500
Possible hydrogen bond	0.409	0.500
rms deviation from ideal torsion angles (*)		
For prespecified φ, ψ angles	30.8	15.0
For planar group (0 or 180)	6.3	3.0
For staggered group (± 60 or 180)	26.9	15.0
For orthonormal group (± 90)	28.1	15.0

^{*}The weight for the structure factor refinement was obtained from the equation $\omega = (1/\sigma)^2$, where $\sigma =$

of the light and heavy chains were altered to correspond to those of the 4-4-20 Fab.34 The model of the 4-4-20 Fab was improved through alternating cycles of refinement and interactive model building on an Evans and Sutherland PS300 graphics system with the FRODO program. 35,36 Polypeptide backbones and amino acid side chains were fitted to $2F_0 - F_c$ maps, in which Fo and Fc were observed and calculated structure factors. Fluorescein was located in a $\Delta F (F_0 - F_c)$ map, for which the phase angles were calculated from the refined atomic model of the protein (atomic coordinates for fluorescein were omitted). The ligand-protein complex was subjected to additional cycles of refinement until the R factor $(\Sigma || F_o | - | F_c || / \Sigma || F_o ||)$ began to plateau at its current value of 0.180 (before idealization of bond lengths and angles; 0.215 after).

RESULTS

Description of the Three-Dimensional Structure of the Fluorescein-Fab Complex

The results of the crystallographic refinement of the complex are presented in Table I. This structure could be refined very quickly because of the great similarities with the structure of the unliganded BV04-01 Fab.

Figure 1 contains the three-dimensional "cage" electron density to which a skeletal model of fluorescein was fitted by interactive computer graphics. The torsion angle measured between the xanthonyl and benzoyl rings was 73° in the bound hapten.

An αC skeletal model of the 4-4-20 Fab is shown as a stereo pair in Figure 2, with a model of fluorescein codisplayed in the binding site. Tracings of the αC chains of the 4-4-20 and BV04-01 Fabs are superimposed in Figure 3. Details of the structures of the ligand and combining site are presented in Figure 4 (skeletal models). Solvent-accessible surfaces³⁷ are illustrated in Figure 5. Amino acid sequences³⁴ for the hypervariable regions are listed in Figure 6.

Polypeptide chains could be traced unambiguously in both the light and heavy chains of the 4-4-20 complex. Significantly, the third hypervariable loop, which was difficult to follow in the heavy chain of the BV04-01 Fab, was well defined in the fluorescein—Fab complex. In the presence of ligand, constituents of this loop were found to have small temperature factors (B values), characteristic of regions with low mobility.

Comparison of the Structures of the 4-4-20 and BV04-01 Fabs


The 4-4-20 Fab is an extended molecule in which the pseudotwofold axes between the pairs of variable and constant domains are nearly colinear (i.e., the measured "elbow bend" angle between the two pseudodiads is 171°). Except for the third hypervariable loops, in which the 4-4-20 heavy chain is shorter than the BV04-01 sequence by three residues, the α C tracings are remarkably similar in the two proteins. This similarity is readily understand-



 $^{40 - 278 \}times [\sin(\theta)/\lambda - 1/6].$

[†]Average temperature factor. ‡Resolution limits of 2.7–6.0 Å.

Explicit hydrogen bonds for β-pleated sheets.






Fig. 1. Three-dimensional electron density (orange) corresponding to fluorescein (green) in the combining site of the 4-4-20 Fab. This electron density was obtained in a difference Fourier map after crystallographic refinement of the ligand-protein complex. A skeletal model of fluorescein was fitted to the electron-density by interactive computer graphics.

Fig. 2. Stereo diagram of α C tracings of the light (blue) and heavy (red) chains of the 4-4-20 Fab, with fluorescein (green) in the combining site. The "variable" domains are at the top and the "constant" domains are at the bottom. Disulfide bonds are represented by yellow bars.






Fig. 3. Superimposed αC tracings of the 4-4-20 and BV04-01 Fabs, the latter having specificity for single-stranded DNA. The two chains of the 4-4-20 Fab are colored red (heavy) and blue (light). The 4-4-20 Fab was cocrystallized with fluorescein in 2-methyl-2,4-pentanediol and the BV04-01 Fab was crystallized without ligand in ammonium sulfate. Yet the two crystals were nearly isomorphous and the structures of the Fabs were very similar.

able in the light chains, which differ in only six amino acid positions. However, there are 42 replacements in the variable domain of the 4-4-20 heavy chain. Substitutions that appear to be critical for the binding of fluorescein are arginine 39 for histidine and tryptophan 101 for leucine in the light chain; tryptophan 33 for alanine and glutamine 50 for arginine in the heavy chain. Because of differences in the lengths of the third hypervariable loops, tyrosine 102 and 103 have no direct counterparts in the BV04-01 Fab. Interestingly, arginine 39 is replaced by histidine in other members of the antifluorescyl idiotype family and by glutamine in the Mcg Bence-Jones dimer. This glutamine is located outside the regions available for ligand binding. 12

Fluorescein Binding Site

Fluorescein fits into a slot lined by constituents of both the light and heavy chains (see Figs. 4 and 5), and participates in a network of interacting aromatic groups with the protein. There are 68 pairs of atoms of the ligand and protein separated by <4 Å. Of the potential interactions, 42 are associated with the xanthonyl moiety and 26 with the benzoyl group of fluorescein. This distribution is consistent with the assignment of the xanthonyl moiety as the "immunodominant" portion of the hapten.

Tryptophan L101 forms the bottom of the slot and tryptophan H33 and tyrosine L37 provide the sides. The width of the slot, as measured from the distance between the centroids of the rings of tryptophan H33 and tryosine L37, is about 9 Å. The phenolic ring of tyrosine L37 is stacked with the xanthonyl moiety of fluorescein. Tryptophan H33 interacts with the hapten to produce an aromatic pair of the type described by Burley and Petsko.³⁸ One enolic group (oxygen 1) on the xanthonyl ring is only 3.0 Å from an imidazolium nitrogen of histidine L31. The other enolic group (oxygen 3) is sufficiently close (2.8 Å) to the guanido group of arginine L39 for an electrostatic interaction and is also within hydrogen bonding distance of serine L96. Thus one of the ligand's two negative charges is neutralized by the antibody. $\bullet x$ ygen 2, in the ether linkage at the top of the middle ring of the xanthonyl moiety, does not participate in interactions with the protein.

Surprisingly, the second negative charge on fluorescein (the carboxylic acid) is not formally neutralized by a protein substituent. Instead, this group faces the solvent at an open end of the slot. Partial charge compensation is achieved by the formation of a hydrogen bond between the phenolic hydroxyl group of tyrosine L37 and one of the carboxylic acid oxygen atoms (the electron density in a $2F_0$ – F_c map is continuous between the two sets of atoms).

Tyrosine 103 extends toward the phenyl ring of fluorescein and tyrosine 102 contributes to the structural integrity of the binding site without actually being in contact with the hapten (see Fig. 4). There is a clear solvent channel for a lysine side chain to be connected to an isothiocyanate group in the para position of the phenyl ring, as would be expected for a hapten coupled to the KLH carrier protein in the immunogen. This solvent channel is shown in Figure 5.

Glutamine H50, which replaces an important arginine residue in the putative binding site of the BV04-01 Fab, is mostly buried in the presence of fluorescein in the 4-4-20 Fab. However, the polar end of the side chain (the carbonyl oxygen of the amide group) is within hydrogen bonding distance of the indole nitrogen of tryptophan H33. Arginine H52, another key residue in the BV04-01 binding region, is salt bridged to glutamic acid H59 (an alanine in BV04-01).



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

